CATALYST PHARMACEUTICALS, INC.
DelistedCIK 1369568fmd_1RF4DJG9Y2GJ46NE4DHE174N6BManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 04, 2002 to Mar 31, 2026, 72 periods
Latest annual · FY2025
Millions- Total revenues
- 589
- Gross profit
- 502
- Operating income
- 258
- Net income
- 214
- Free cash flow
- 209
Latest quarter · Q1 FY2026
Millions- Total revenues
- 149
- Gross profit
- 135
- Operating income
- 73
- Net income
- 64
- Free cash flow
- 60
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +40.1%
- Revenue, 5 yearsFY2020 to FY2025
- +37.7%
- Net income, 5 yearsFY2020 to FY2025
- +23.4%
CATALYST PHARMACEUTICALS, INC. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $589 million | $491.7 million | +19.8% | 10-K 2026-02-25 · proof |
| Gross profit | $501.7 million | $422.9 million | +18.6% | 10-K 2026-02-25 · proof |
| Operating income | $257.8 million | $195.1 million | +32.1% | 10-K 2026-02-25 · proof |
| Net income | $214.3 million | $163.9 million | +30.8% | 10-K 2026-02-25 · proof |
| Cash from operating activities | $208.7 million | $239.8 million | -13% | 10-K 2026-02-25 · proof |
| Free cash flow | $208.6 million | $239.3 million | -12.8% | 10-K 2026-02-25 · proof |
| Total assets | $1.1 billion | $851.4 million | +29.7% | 10-K 2026-02-25 · proof |
| Total liabilities | $149.7 million | $123.8 million | +21% | 10-K 2026-02-25 · proof |
| Cash and cash equivalents | $709.2 million | $517.6 million | +37% | 10-K 2026-02-25 · proof |
- What was CATALYST PHARMACEUTICALS, INC.'s revenue in fiscal 2025?
- CATALYST PHARMACEUTICALS, INC. reported revenue of $589 million for fiscal 2025 (the year ended Dec 31, 2025), against $491.7 million the year before (+19.8%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What was CATALYST PHARMACEUTICALS, INC.'s gross profit in fiscal 2025?
- CATALYST PHARMACEUTICALS, INC. reported gross profit of $501.7 million for fiscal 2025 (the year ended Dec 31, 2025), against $422.9 million the year before (+18.6%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What was CATALYST PHARMACEUTICALS, INC.'s operating income in fiscal 2025?
- CATALYST PHARMACEUTICALS, INC. reported operating income of $257.8 million for fiscal 2025 (the year ended Dec 31, 2025), against $195.1 million the year before (+32.1%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What was CATALYST PHARMACEUTICALS, INC.'s net income in fiscal 2025?
- CATALYST PHARMACEUTICALS, INC. reported net income of $214.3 million for fiscal 2025 (the year ended Dec 31, 2025), against $163.9 million the year before (+30.8%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What was CATALYST PHARMACEUTICALS, INC.'s cash from operating activities in fiscal 2025?
- CATALYST PHARMACEUTICALS, INC. reported cash from operating activities of $208.7 million for fiscal 2025 (the year ended Dec 31, 2025), against $239.8 million the year before (-13%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What was CATALYST PHARMACEUTICALS, INC.'s free cash flow in fiscal 2025?
- CATALYST PHARMACEUTICALS, INC. reported free cash flow of $208.6 million for fiscal 2025 (the year ended Dec 31, 2025), against $239.3 million the year before (-12.8%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What are CATALYST PHARMACEUTICALS, INC.'s total assets?
- As of Dec 31, 2025, CATALYST PHARMACEUTICALS, INC. reported total assets of $1.1 billion, against $851.4 million a year earlier (+29.7%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What are CATALYST PHARMACEUTICALS, INC.'s total liabilities?
- As of Dec 31, 2025, CATALYST PHARMACEUTICALS, INC. reported total liabilities of $149.7 million, against $123.8 million a year earlier (+21%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What are CATALYST PHARMACEUTICALS, INC.'s cash and cash equivalents?
- As of Dec 31, 2025, CATALYST PHARMACEUTICALS, INC. reported cash and cash equivalents of $709.2 million, against $517.6 million a year earlier (+37%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1369568&period_type=annual&limit=5"Information only, not investment advice.